Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Exclusion Criteria

• •Peripheral neuropathy that is greater or equal to Grade 2
• •Cardiac status as described in protocol
• •Severe diarrhea (≥ Grade 3) not controllable with medication or requires administration of total parenteral nutrition
• •Known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption of tolerance of MLN9708
• •Uncontrolled infection requiring systematic antibiotics
• •Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
• •Presence of other active malignancy with the exception of nonmelanoma skin cancer, cervical cancer, treated early-stage prostate cancer provided that prostate-specific antigen is within normal limit, or any completely resected carcinoma in situ
• •Female participants who are lactating or pregnant
• •Major surgery within 14 days before the first dose of study drug
• •Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol